SDC is Switzerland's international cooperation agency within the Federal Department of Foreign Affairs (FDFA). The SDC's engagement in health revolves around three issues: the strengthening of health systems; the fight against communicable and noncommunicable diseases; and improving sexual, reproductive, maternal, neonatal, and child health. The SDC is active in low and middle-income countries (in both stable and fragile contexts), as well as in transition countries.Main activities: political dialogue, program and strategic partnerships, thematic council, knowledge management, internal and external communication

Communal Councillor at Commune de Vuarrens (VD), delegate at the ASIRE. The purpose of the ASIRE is to provide for the needs of compulsory education at the expense of the communes for the primary and secondary levels.

The IICT programme is targeted at researchers who wish to conduct an investigator initiated clinical trial. Support will be given to trials that are of value to the patients and address important unmet medical and societal needs but are not in industry focus.

THINK RARE is a team of highly qualified experts with an inspirational ability to unite and empower people to go beyond their vision.THINK RARE professionals provide consultancy services, expertise and individualized solutions for companies to meet their challenges in an innovative and rapid-changing environment. THINK RARE services range from networking opportunities to branding and visual identity in respect of a company vision. An organisation adapting to an innovative world is an enterprise ready to welcome their new generation of clients.> Main activities: consultant, strategic thinking development, marketing, public relations and promotion, healthcare management.

The Swiss Personalized Health Network (SPHN) is a national initiative designed to promote the development of personalized medicine and personalized health in Switzerland. SPHN will lay the foundations that are needed to facilitate research projects in this area such as a system for a nationwide exchange of health-related data. The ultimate goal is to promote health and well-being, to prevent, diagnose and treat unfavourable health conditions more precisely, thus reducing the risk of developing such conditions and permitting more effective treatments of disease states with fewer adverse effects.

Chelonia lives at the intersection of scientific invention, technology and entrepreneurship. Our mission is to make the innovation useful to end-users and people.

Rare Diseases International’s mission is to be the voice of people living with rare diseases worldwide. One of the point of the RDI’s Joint Declaration includes research as a policy priority with international value-added; it is deemed necessary to constitute a Working Group to work specifically on promoting rare disease research at the international level.The main missions of the working group are:- Elevating rare disease research to the status of global public health priority- Providing expert opinion and produce or endorse existing position papers- Providing expert opinion and input on policies

The RE(ACT) Congress – International Congress of Research on Rare and Orphan Diseases – was initiated in 2012 by the BLACKSWAN Foundation to create a forum for and promote scientific cooperation and research on rare and orphan diseases.

Swiss Alliance of rare disease patient organizations

The BLACKSWAN Foundation was established in Switzerland in 2010 to contribute to the development of research on rare and orphan diseases worldwide. The Foundation supports research on all different types of rare and orphan disease, which makes its vision unique and helps in finding new solutions that can assist a large variety of projects. Besides its funding research mission, the Foundation organizes every two years the RE(ACT) Congress (https://www.react-congress.org), which became an international reference point for rare disease experts. In three editions, more than 1,500 scientists were able to establish approximately fifty collaborations. In 2014, the BLACKSWAN Foundation launched the RE(ACT) Community (http://react-community.org) a crowdfunding and a knowledge sharing digital platform that connects researchers, patients and other rare disease stakeholders. Since 2015, BLACKSWAN Foundation has also started an international advocacy and awareness campaign called #RAREvolution to ensure rare diseases are recognized as an international public health and research priority.> Main activities: corporate brand and communication strategy, public relations, increase the knowledge on orphan diseases and research. Initiator and organizer of the first International Congress on Research of Rare and Orphan Diseases: RE(ACT) Congress with more than 1500 attendees, fundraising.

I am in charge to evaluate the scientific content of the grants asked to the association AEMO for children with orphan diseases and their families.

The RE(ACT) Discovery Institute is the therapeutic discovery arm of the no-profit BLACKSWAN Foundation, a renowned Foundation globally active in rare diseases research and advocacy.The RE(ACT) Discovery Institute aims to fill the gap between the public-funded basic science research and the industrial supported applied R&D, allowing the Swiss and world scientific community to work on a specific mechanism, target protein, or process involved in disease onset progression to move their research from the bench to the bedside. Besides the BLACKSWAN Foundation's leadership, partnerships will be created with national or international Universities, Federal Institutes of Technology and hospitals, universities, research institutes, foundations, or patient associations interested in translational research and development.Main activities: operational management, communicating and implementing the strategy, facilitating business growth, representing the institute, relations with partners, developing annual investment plans, coordinating the preparation of budgets, IP, and patent prosecution.

The Health 2030 Genome Center aims to be the national and an international leader in genomic medicine to advance research and improve human health.The Health 2030 Genome Center is a multi-institutional hub to promote genomic medicine in Switzerland. The Center is the genomic medicine arm of the Health 2030 initiative for Swiss personalized medicine. The institutions collaborating in the Health 2030 Initiative are the École Polytechnique Fédérale de Lausanne (EPFL), Geneva University Hospitals (HUG), University of Geneva (UNIGE), Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne (UNIL), Bern University Hospital (InselSpital) and University of Bern (UNIBE).

radiz aims to improve the treatment and outcome of patients with rare diseases and to establish Zurich as one of the leading centers in the field of rare diseases in Europe. A great emphasis is placed on the transition from pediatric to adult medicine.

The Genolier Foundation is the philanthropic body of the private clinics Swiss Medical Network to support patient in difficulty, medical humanitarian project, formation, learning and research.> Main activities: revitalization of the Foundation (existing since 1986), strategic development, marketing, public relations and promotion. Projects management (corporate social responsibility, humanitarian, medical and research).

SanOrphan SA is a drug discovery and development company committed to the development of innovative therapeutics for the treatment of rare and devastating lysosomal storage diseases with high unmet medical needs.> Main activities: company and strategy establishment, investors prospecting, academic partnerships, IP and patent prosecution.

I am working on a project of ex situ gene therapy of metabolic liver diseases using lentiviral-mediated transduction of deficient hepatocytes followed by immediate auto-transplantation.> Main activities: management of the gene therapy research laboratory for pediatric surgery (4 subordinates), supervise the research in the laboratory (3 projects), develop preclinical and clinical studies (GLP and GMP), teaching to medical students (APP) and supervision of master works, scientific presentation (national and international meetings), grants writing.

Teacher for medical student (2nd and 3rd years) at the “Reproduction Unit”. APP: Apprentissage Par Problème

Travail dans le cadre d'une future application du protocole de thérapie génétique établi dans notre laboratoire sur des modèles animaux pour une alternative aux transplantations hépatiques chez l'enfant présentant des maladies métaboliques.

Molecular engineering, lentiviral vectors

By expressing the human telomerase reverse transcriptase (hTERT) in human CD8+ T lymphocytes I elucidated some cellular mechanisms regulating the proliferative potential and studied its possible application in immunotherapy against cancer.

A database of information on rare diseases and orphan drugs for all publics. Its aim is to contribute to the improvement of the diagnosis, care and treatment of patients.> Main activities: implementation, extension and development of the Orphanet Web database (www.orpha.net) in Switzerland, establishment and management of a scientific advisory board, international partnerships.